Delivery Order SPE2DB20D1110-SPE2DB23FK43V

Award Date 9/25/23
Potential Completion Date 9/26/23
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $36,950.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm-fixed-price delivery order contract with a completion date of July 8, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $12,737.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 MG tablets, a medication used to treat overactive bladder. The award has an ultimate completion date of October 25, 2024 and is structured as a firm fixed-price delivery order. This contract does not have a set-aside designation, indicating...
This federal contract award, valued at $44,613.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm fixed-price delivery order contract with a completion date of January 3, 2025. The contract does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $10,445.58, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 29, 2024. The award is not associated with a set-aside program, indicating open...
This federal contract award, valued at $27,760.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order with a completion date of July 18, 2024. It is not associated with a set-aside designation, indicating open competition....
This federal contract award, valued at $18,474.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm fixed-price delivery order contract with a completion date of July 1, 2024. The contract does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $9,601.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $11,601.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order, with an ultimate completion date of July 29, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award, valued at $58,590.06, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. This is a firm-fixed-price delivery order contract with an ultimate completion date of October 18, 2023. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award, valued at $13,354.79, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the procurement of Myrbetriq ER 50 mg Tablets, a medication used for the treatment of overactive bladder. The contract has an ultimate completion date of June 20, 2024 and is structured as a Firm Fixed Price agreement. This contract award is not designated with...
  • SPE2DB20D1110
    Indefinite Delivery Contract
  • SPE2DB20D1110-SPE2DB23FK43V
    Delivery Order

This federal contract award, valued at $3,275.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used for the treatment of overactive bladder. The contract has an ultimate completion date of September 26, 2023 and is a delivery order with a firm fixed price pricing type. The contract award was not set aside for any specific business type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/12/25, 9:53 AM